Researchers at CSIR-CCMB have identified new drug targets in TB-causing bacteria using CRISPR technology. By studying two protein export pathways — SecA1 and Tat — they found that blocking these routes slowed bacterial growth and damaged cell membranes. The breakthrough could help develop new treatments, especially critical as drug-resistant TB rises in high-burden countries like India.